Share on LinkedInShare on LinkedIn

ARTICLE · 05 APRIL 2018

Additional Discovery Of Clinical Trial Data In Inter Partes Review

BakerHostetler
BakerHostetler
Contributor
BakerHostetler

BakerHostetler

Recognized as an innovator and one of the top firms for client service, BakerHostetler helps...

View firm profile
Explore more from BakerHostetler

In Apotex, Inc. et al. v. Novartis AG (IPR 2017-00854, paper 47 dated Feb. 5, 2018), petitioner Apotex sought, and was granted, discovery of a Phase III clinical trial protocol from patent owner Novartis.

United StatesIntellectual Property

In Apotex, Inc. et al. v. Novartis AG (IPR 2017-00854, paper 47 dated Feb. 5, 2018), petitioner Apotex sought, and was granted, discovery of a Phase III clinical trial protocol from patent owner Novartis.

The patent at issue in the IPR, U.S. 9,187,405, claims a method for treating relapses in relapsing-remitting multiple sclerosis by orally administering fingolimod "at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen." In its petition for IPR, Apotex alleged that the prior art taught that 0.5 mg of fingolimod was known to be an effective maintenance dose for treating multiple sclerosis. Novartis responded that to the extent that the prior art taught the use of 0.5 mg of fingolimod, it was only in the context of a treatment wherein the maintenance dose is preceded by a loading dose, something that is explicitly absent from the claimed methods. See paper 8 at 25.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from